300760 Shenzhen Mindray Bio-Medical Electronics
- 304.26
- -7.34-2.36%
Shenzhen Mindray Bio-Medical Electronics News
Mindray Healthcare (300760.SZ): The company's products in the field of medical imaging include ultrasound diagnostic systems, digital X-ray imaging systems, and PACS
On May 7, Ge Longhui Medical (300760.SZ) said on the investor interactive platform that the company's products in the field of medical imaging include ultrasound diagnostic systems, digital X-ray imaging systems, and PACS. In the field of ultrasound diagnostic systems, we provide hospitals, clinics, imaging centers, etc. with a full range of ultrasound diagnostic systems covering ultra-high-end to low-end, as well as specialized solutions for gradually segmented applications in different clinical specialties such as radiology, obstetrics and gynecology, intervention, emergency, anesthesia, severe illness, and liver fiber. In the field of digital X-ray imaging, the company provides radiology departments, ICU, and emergency departments including mobile, double column, and suspended models
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Investors in Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) had a good week, as its shares rose 7.1% to close at CN¥305 following the release of its quarterly results. Results
Mindray Healthcare (300760.SZ): Model of “Made in China” for medical devices
On the eve of the long holiday, the A-share market performed well. Following a single-day northbound capital inflow that hit a record high since the opening of the Mainland Stock Connect on April 26, the three major A-share indices collectively surged in the intraday market on April 29, and the Shanghai Composite Index once again reached 3,100 points, returning to the annual line. Among them, Mindray Healthcare, the leading medical device company that just released its 2023 report and 2024 quarterly report, also rose sharply with an excellent report card, with an intraday increase of more than 6%. The net capital inflow reached 420 million yuan on the same day, and the net purchase of Land Stock Connect reached 227 million yuan, showing impressive performance. Chart 1: Mindray Healthcare's stock price performance Data source: WIND, GEG
Mindray Healthcare (300760.SZ) obtains control of Huitai Healthcare
Mindray Healthcare (300760.SZ) announced that as of the date of this announcement, Cheng Zhenghui held Huitai Medical 1251.9...
Nomura Adjusts Shenzhen Mindray Bio-Medical Electronics' Price Target to 422.45 Yuan From 441.50 Yuan, Keeps at Buy
03:42 AM EDT, 04/29/2024 (MT Newswires) -- Nomura Adjusts Shenzhen Mindray Bio-Medical Electronics' Price Target to 422.45 Yuan From 441.50 Yuan, Keeps at Buy Price (RMB): ¥302.11, Change: ¥+13.31,
Gelonghui Announcements Selected | Mindray Healthcare: Net profit increased 22.9% to 3.16 billion yuan in the first quarter, and all three major international business lines achieved rapid growth; Yunnan Baiyao: Net profit of 1.702 billion yuan in the fir
[Performance data] Sanan Optoelectronics (600703.SH): Net profit of 367 million yuan in 2023, and plans to distribute 0.3 yuan Sanan Optoelectronics (600703.SH) to release the 2023 annual report, achieving operating income of 14.53 billion yuan, an increase of 6.28%; net profit attributable to shareholders of listed companies was 367 million yuan, a year-on-year decrease of 46.50%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - $1,088 million, with basic earnings per share of 0.07 yuan. It is proposed to distribute a cash dividend of 0.30 yuan (tax included) for every 10 shares to all shareholders. Changsha silver
The third generation of medicine has lost 150 billion
Growth is still ongoing
North and South Water | Beishui made a significant net purchase of nearly HK$10 billion, increasing CNPC's inventory for 5 consecutive days; Nanshui raised more than 200 million yuan from Maotai
Track the latest developments in north-south funding
The Total Return for Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on a lighter note, a good company can see its share price rise well over
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Here's What Shenzhen Mindray Bio-Medical Electronics' (SZSE:300760) Strong Returns On Capital Mean
If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in con
Guolian Securities: Medical AI empowers the healthcare industry chain and focuses on companies with leading technology layout and strong commercialization capabilities
Healthcare is one of the important fields of large-scale application of artificial intelligence technology (AI).
Mindray Healthcare (300760.SZ): Applying AI Functions Combining Big Data and Intelligent Algorithms to Medical Devices
Gelonghui, March 20 | Mindray Healthcare (300760.SZ) said on an interactive platform that compared to the lack of appropriate diagnostic and treatment tools, the scarcity of experienced healthcare personnel is a more important reason for the scarcity of high-quality medical resources, and the training of such personnel not only requires a large amount of capital investment, but more importantly, it takes a very long time. We believe that applying AI capabilities combined with big data and intelligent algorithms to medical devices will be an effective way to solve the scarcity of experienced healthcare workers more quickly. In fact, many multi-pound products the company has launched since 2015, such as N
Guojin Securities: Medical equipment updates are expected to accelerate demand for high-end innovative medical equipment is expected to be released
It is recommended to focus on segments such as surgical robotics, endoscopes, ultrasound, and ICU equipment.
Guotai Junan: The medical device procurement side is expected to improve season by season, and the boom has quietly arrived
The medical device procurement side is expected to improve quarter by season, and the boom has quietly arrived.
Nomura Adjusts Shenzhen Mindray Bio-Medical's Price Target to 441.20 Yuan From 423.39 Yuan, Keeps at Buy
04:34 AM EDT, 03/12/2024 (MT Newswires) -- Nomura Adjusts Shenzhen Mindray Bio-Medical's Price Target to 441.20 Yuan From 423.39 Yuan, Keeps at Buy Price (RMB): ¥305.42, Change: ¥+0.83, Percent Change
Guoxin Securities: Focus on the immediate needs of medical care, focus on the high growth targets of the first quarter report
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Owning 56% in Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Means That Insiders Are Heavily Invested in the Company's Future
Key Insights Insiders appear to have a vested interest in Shenzhen Mindray Bio-Medical Electronics' growth, as seen by their sizeable ownership A total of 2 investors have a majority stake in the co
Aweite (873693): The main products provided to Mindray Healthcare include structural parts of blood oxygen analyzers, structural parts of injection pumps, etc.
Gelonghui, March 6 | Aweite (873693) recently said during a survey reception from institutional investors that the main products the company provides to Mindray Healthcare include structural parts for blood oxygen analyzers, injection pump structural parts, etc. Mindray Healthcare has cooperated with our company for many years, and the business relationship is quite close. In order to more conveniently serve customers in South China, including Mindray Healthcare, quickly respond to customer needs, and develop business in the South China market, the company set up a Shenzhen Aviate factory in Shenzhen in 2020. Shenzhen Aweite was put into operation the same year it was established. In the future, Avite will continue to step up efforts to provide better products for Mindray Healthcare.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Shares Could Be 24% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shenzhen Mindray Bio-Medical Electronics fair value estimate is CN¥391 Shenzhen Mindray Bio-Medical Electronics is estimated to be 24% underv
Analysis
Price Target
No Data
